Literature DB >> 19788928

Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances.

Daniel F Legler1, Markus Bruckner, Edith Uetz-von Allmen, Petra Krause.   

Abstract

Prostaglandin E(2) (PGE(2)) is the most abundant eicosanoid and a very potent lipid mediator. PGE(2) is produced predominantly from arachidonic acid by its tightly regulated cyclooxygenases (COX) and prostaglandin E synthases (PGES). Secreted PGE(2) acts in an autocrine or paracrine manner through its four cognate G protein coupled receptors EP1 to EP4. Under physiological conditions, PGE(2) is key in many biological functions, such as regulation of immune responses, blood pressure, gastrointestinal integrity, and fertility. Deregulated PGE(2) synthesis or degradation is associated with severe pathological conditions like chronic inflammation, Alzheimer's disease, or tumorigenesis. Therefore, pharmacological inhibition of COX enzymes and PGE(2) receptor antagonism is of great therapeutic interest. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19788928     DOI: 10.1016/j.biocel.2009.09.015

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  79 in total

1.  Identification of a novel class of anti-inflammatory compounds with anti-tumor activity in colorectal and lung cancers.

Authors:  Hui-Hua Chang; Zuohe Song; Lee Wisner; Tina Tripp; Vijay Gokhale; Emmanuelle J Meuillet
Journal:  Invest New Drugs       Date:  2011-09-20       Impact factor: 3.850

Review 2.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Authors:  Jocelyn Reader; Dawn Holt; Amy Fulton
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 3.  MicroRNA and AU-rich element regulation of prostaglandin synthesis.

Authors:  Ashleigh E Moore; Lisa E Young; Dan A Dixon
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

4.  Reduced T cell-dependent humoral immune response in microsomal prostaglandin E synthase-1 null mice is mediated by nonhematopoietic cells.

Authors:  Fumiaki Kojima; Andrey Frolov; Rahul Matnani; Jerold G Woodward; Leslie J Crofford
Journal:  J Immunol       Date:  2013-10-14       Impact factor: 5.422

5.  Silymarin and celecoxib ameliorate experimental varicocele-induced pathogenesis: evidences for oxidative stress and inflammation inhibition.

Authors:  Sara Mazhari; Mazdak Razi; Rajabali Sadrkhanlou
Journal:  Int Urol Nephrol       Date:  2018-04-05       Impact factor: 2.370

6.  Prostaglandin E2 triggers cytochrome P450 17α hydroxylase overexpression via signal transducer and activator of transcription 3 phosphorylation and promotes invasion in endometrial cancer.

Authors:  Jieqi Ke; Zhen Shen; Min Li; Cheng Peng; Ping Xu; Meimei Wang; Yi Zhu; Xuefen Zhang; Dabao Wu
Journal:  Oncol Lett       Date:  2018-07-18       Impact factor: 2.967

7.  PGE2 modulates the transcriptional activity of ERRa in prostate stromal cells.

Authors:  Zhaochen Ning; Xiaoling Du; Ju Zhang; Kuo Yang; Lin Miao; Yan Zhu; Hui Yuan; Linlin Wang; Helmut Klocker; Jiandang Shi
Journal:  Endocrine       Date:  2014-04-24       Impact factor: 3.633

Review 8.  Prostanoid signaling: dual role for prostaglandin E2 in neurotoxicity.

Authors:  Dejan Milatovic; Thomas J Montine; Michael Aschner
Journal:  Neurotoxicology       Date:  2011-03-03       Impact factor: 4.294

Review 9.  Efficacy of acupuncture in the treatment of chronic prostatitis-chronic pelvic pain syndrome: a review of the literature.

Authors:  Junaid Wazir; Rahat Ullah; Shihong Li; Md Amir Hossain; Maladho Tanta Diallo; Farhan Ullah Khan; Awais Ullah Ihsan; Xiaohui Zhou
Journal:  Int Urol Nephrol       Date:  2019-08-29       Impact factor: 2.370

10.  Intracellular EP2 prostanoid receptor promotes cancer-related phenotypes in PC3 cells.

Authors:  Ana Belén Fernández-Martínez; Javier Lucio-Cazaña
Journal:  Cell Mol Life Sci       Date:  2015-04-01       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.